Microbot Medical receives first Japanese patent for LIBERTY

Microbot Medical Inc., the developer of the LIBERTY Endovascular Robotic System, in the present day mentioned the Japanese Patent Workplace has granted the corporate its first patent in Japan. The patent covers the core LIBERTY know-how, corresponding to a compact robotic system for driving and manipulating the motion of a minimum of one elongate surgical device.

As well as, the Hingham, Mass.-based firm has acquired patents within the U.S., China, and Israel over the previous 90 days. It additionally earned 510(okay) clearance from the U.S. Meals and Drug Administration (FDA) for LIBERTY in September.

“Our preliminary focus is on the U.S. market. Nonetheless, sure markets, corresponding to Japan, symbolize enticing and strategically vital markets for the LIBERTY System,” mentioned Harel Gadot, chairman, president, and CEO of Microbot. “Constructing on our latest FDA clearance of LIBERTY, we’re evaluating alternatives to increase into different world markets which have historically taken FDA clearance into consideration to doubtlessly expedite native approval and adoption.”

Based in 2010, Microbot Medical is targeted on remodeling endovascular procedures by superior robotic know-how.

LIBERTY guarantees exact, distant operation

LIBERTY is an endovascular robotic system for interventional physicians and hospitals in search of to enhance procedural precision, security, and effectivity, in accordance with Microbot Medical. In contrast to conventional handbook methods, it provides a single-use, compact design that permits managed distant operation, the corporate claimed.

The surgical robotic can be utilized in neurovascular, cardiovascular, and peripheral vascular procedures. Microbot added that LIBERTY might decrease process prices and enhance the general high quality of care.

In August, Microbot introduced a brand new patent overlaying a modular robotic surgical system. The system features a base and a number of tool-receiver items organized as separate items. These items are independently and interchangeably attachable to the bottom. The corporate mentioned the patent might permit it to adapt Liberty for a wider vary of endovascular procedures.

Microbot Medical to lift $92M from inventory sale

Microbot Medical final month mentioned buyers agreed to train excellent most popular funding choices, which might generate as much as $92.2 million in gross proceeds. It intends to make use of the proceeds to help improvement, commercialization, and regulatory work for its LIBERTY system.

The corporate additionally plans to pursue potential acquisitions, increase purposes of its mental property, and use the funding for working capital and common company functions. Microbot mentioned the newest developments have accelerated its business launch plans.